Corbus Pharmaceuticals
CRBP
S$12.33
Share price
3.56%
Change (1 day)
-83.50%
Change (1 year)
Categories
Earnings for Corbus Pharmaceuticals (CRBP)
Earnings in 2025 (TTM): -S$65.65 Million
According to Corbus Pharmaceuticals 's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -S$49.31 Million, an increase over its 2023 earnings that were of -S$57.7 Million. The earnings displayed on this page is the company's Pretax Income.
Earnings history for Corbus Pharmaceuticals from 2014 to 2025
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2025 (TTM)  | -S$65.65 Million | 33.13% |
| 2024 | -S$49.31 Million | -14.54% |
| 2023 | -S$57.7 Million | 28.56% |
| 2022 | -S$44.88 Million | -37.68% |
| 2021 | -S$72.01 Million | -54.41% |
| 2020 | -S$0.16 Billion | 59.28% |
| 2019 | -S$99.17 Million | 35.87% |
| 2018 | -S$72.99 Million | 74.27% |
| 2017 | -S$41.88 Million | 62.94% |
| 2016 | -S$25.71 Million | 125.82% |
| 2015 | -S$11.39 Million | 251.68% |
| 2014 | -S$3.24 Million |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Vanda Pharmaceuticals VNDA | -S$93.19 Million | 47.10% | 🇺🇸 USA |
 Viking Therapeutics
VKTX | -S$0.17 Billion | 160.35% | 🇺🇸 USA |
 Epizyme EPZM | -S$0.24 Billion | 272.74% | 🇺🇸 USA |
 Advaxis ADXS | -S$43.76 Million | -30.92% | 🇺🇸 USA |